Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients - Wikidata - awgldk - TriplyDB

Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients

Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients

http://www.wikidata.org/entity/Q37252523

about

A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review Drug delivery systems and combination therapy by using vinca alkaloids Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer.Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor The antifolates Prospects in folate receptor-targeted radionuclide therapy Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.Liposomes targeting tumour stromal cells.New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer.EC145: a novel targeted agent for adenocarcinoma of the lung.Soft structure formation and cancer cell transport mechanisms of a folic acid-dipeptide conjugate.Vintafolide: a novel targeted agent for epithelial ovarian cancer.Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance.A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

P2860

Q26781856-E1725DA2-FABB-4410-A4D0-7B85322CDB5E Q26828581-5EF70681-62E3-49BE-95C3-55D6DF481926 Q28829009-366E4E90-B6F4-4923-B6AB-E1D298DC1D38 Q33923397-CE57B9C3-B5EF-4FA0-A6C6-4F9B9745C628 Q35236565-7FDB6CD9-10CB-443D-B147-D73F8D874596 Q35780797-1B430743-F246-466D-ABD2-A42667CA08B6 Q36226627-5AC87994-C26E-4D03-A6BC-B28A94BEB0D5 Q36557169-6ABF11FF-6740-4A56-8619-82529D4D9A76 Q37183495-03125CB9-343A-406D-99D3-83BA19D61A14 Q37193061-A399758F-D754-4D72-AF4C-67D6FF820B72 Q37567078-91AD2F1A-BF28-4820-B317-995ADA42357A Q37799613-7DC41DA5-3F4B-46F6-A0C0-CC44F18B06DD Q37809986-0ECCB9CA-15DE-4612-BC6D-3F5DCC45E5EE Q37998528-6B7FB85F-C2E4-4C29-8758-DB78420DE045 Q38913669-630E3798-9B41-41B6-98C4-0AE4193E5DC3 Q39205772-18AEF972-33C6-4D2E-8211-A7DC3D084B5D Q45331579-EFC85115-081B-412B-95D3-5F545724578C Q57975528-69345A08-4AD6-420C-9424-4ACBC5833E9F

P2860

Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients

http://www.wikidata.org/entity/Q37252523

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical pharmacokinetics and ...... ugate EC145 in cancer patients

@en

Clinical pharmacokinetics and ...... gate EC145 in cancer patients.

@nl

type

label

Clinical pharmacokinetics and ...... ugate EC145 in cancer patients

@en

Clinical pharmacokinetics and ...... gate EC145 in cancer patients.

@nl

prefLabel

Clinical pharmacokinetics and ...... ugate EC145 in cancer patients

@en

Clinical pharmacokinetics and ...... gate EC145 in cancer patients.

@nl

P1433

Q37252523-EBDF7CCA-29D1-4C0B-8AB7-F863FE2CF5C7

P1476

Q37252523-E542F32B-D266-488A-8E37-2C18251D2F78

P2093

Q37252523-462A3E17-FE32-49CC-9ED0-8C965978C064

Q37252523-8ED22453-46BA-453E-ABD1-E30980F108B8

Q37252523-B5C6956B-0DDA-4462-A24A-735DD3CABA2B

Q37252523-B880120C-D71E-49DB-B122-5E0EAFE4D126

Q37252523-BECE81CB-76BB-49C2-A842-5E40F3162659

Q37252523-D594E5B0-E172-48C9-BCA0-259244CBD76D

P2860

Q37252523-244005AC-269D-4FD2-A973-73C94FDEDB53

Q37252523-2911991C-C5FD-4A4E-BCD6-B342F5317010

Q37252523-332F0028-F523-4600-AC9A-9B375B5E8361

Q37252523-429AF4ED-5320-4849-B01A-CDB80CAB7F0B

Q37252523-441FF4F9-2ECF-4FB3-8D59-689F148416C2

Q37252523-46B8E18A-6F56-4536-B619-5F9725048F02

Q37252523-48D19099-6BBD-4B4A-A63F-1B291AB49BB6

Q37252523-552E6B58-5B1F-497A-8DFF-CAD8E1C97699

Q37252523-69EF2D84-A4AA-408C-806A-51F36200EB94

Q37252523-907601D4-FE0D-4D25-ADB4-4D67DFC496FB

P304

Q37252523-7BC92A5D-7721-460D-B04F-D75EC7ACFA35

P31

Q37252523-69BCF950-7096-44C1-88D5-4CD735A2F263

P356

Q37252523-483D8B70-8D19-46DF-8F20-4E0D903C8CED

P433

Q37252523-54F91B16-BE28-49AE-822D-124648E05A27

P478

Q37252523-0D99DFA7-77AE-4AB4-8AE1-BED44611AF6B

P50

Q37252523-010FE225-4B62-42FA-B2AF-1A2FF76561E9

P577

Q37252523-D7EBF112-5153-4B3C-B395-94D4B58C753F

P698

Q37252523-C09A6374-FD5A-4894-9883-E544E6B79FC4

P932

Q37252523-98ED346A-F1BF-4646-93F9-875C6928E5E6

P356

0091270009339740

P1433

The Journal of Clinical Pharmacology

P1476

Clinical pharmacokinetics and ...... ugate EC145 in cancer patients

@en

P2093

Christopher P Leamon

http://www.w3.org/2001/XMLSchema#string

Edward A Sausville

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Patricia LoRusso

http://www.w3.org/2001/XMLSchema#string

Patrick J Klein

http://www.w3.org/2001/XMLSchema#string

Richard A Messmann

http://www.w3.org/2001/XMLSchema#string

P2860

Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.

Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical.

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications.

The folate receptor in central nervous system malignancies of childhood.

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Overexpression of folate binding protein in ovarian cancers.

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.

Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.

Preclinical antitumor activity of a novel folate-targeted dual drug conjugate.

The biological chemistry of folate receptors.

P304

1467-1476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270009339740

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19837906

http://www.w3.org/2001/XMLSchema#string

P932

3807256

http://www.w3.org/2001/XMLSchema#string